BioSpace News Archive

JW Therapeutics, an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the initiation of phase I clinical study of JWATM204 in patients with advanced hepatocellular carcinoma.

Arctic Vision announced that the first patient has been enrolled in a Phase III clinical study evaluating ARVN003, a proprietary pilocarpine formulation leveraging its micro dosing platform Optejet®, as a treatment to temporarily improve vision in adults with presbyopia in China.

Biosynth Carbosynth (“Biosynth”), a supplier of critical products and services to the life sciences industry, announces today the acquisition of Pepscan, an expert provider of peptide-based products & services.

Abbisko Therapeutics Co., Ltd. announced completion of dosing of the first patient in the Phase 1 clinical trial in advanced solid tumors for ABSK061, which becomes the first highly selective FGFR2/3 inhibitor advanced into clinical stage globally.

RELIEF THERAPEUTICS Holding SA reported that the parent company, NRx Pharmaceuticals, Inc., of its collaboration partner with respect to aviptadil, NeuroRx, Inc., has announced that the U.S. Food and Drug Administration has declined to issue an Emergency Use Authorization for aviptadil for a subgroup of patients that, in addition to aviptadil, also received remdesivir and continued to progress.

RELIEF THERAPEUTICS Holding SA, announced that it has filed Amendment No. 4 to its Registration Statement on Form 20‑F with the U.S. Securities and Exchange Commission.

Amsterdam, the Netherlands – Royal Philips announced that it has completed the cancellation of 8,758,455 of its shares.